By Business/Source
Currency:AUD
2024/FY
Stock NameRevenueRatio
Development, manufacture and commercialisation of products based on the NovoSorb technology for use103.19M100.00%
By Country/Region
Currency:AUD
2025/FY
Stock NameRevenueRatio
United States Of America96.99M76.22%
Other countries22.31M17.53%
Australia and New Zealand7.95M6.25%
